Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Sergei Filippov (MIPT and Russian Quantum Center at ... Czech Republic, and the Institute of Physics in ... quantum entanglement of particles passing through an amplifier ... distances. Details are provided in an article published ... (see preprint). , Quantum entangled particles are considered ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink ... term. They are the first functional focus beverage to ... an alternative to the temporary fix associated with energy ... July 29, 2014, with hopes to raise $50,000 over ... - http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks ...
(Date:7/23/2014)... Columbia, MD (PRWEB) July 23, 2014 ... Station, an LC/MS amino acid analysis system developed ... analysis, the UF-Amino Station can analyze 38 amino ... , The UF-Amino Station achieves high-speed analysis utilizing ... spectrometer. The LCMS-2020 provides accurate analytical results even ...
(Date:7/23/2014)... July 23, 2014  Having the right people at ... to accelerating business growth and achieving clinical and operational ... (AHA) Leadership Summit, July 20-22, 2014, in ... hospital executives and healthcare experts discussing how partnerships have ... , President & Chief Executive Officer of Cape Regional ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... Ten new validation studies,were published during 2007 ... the total number of studies published to 65., ... increase in interest from US and,European institutes" said ... highly respected academic medical institutions and teaching hospitals,have ...
... notes, and extended the maturity to 2011 on an additional $23.25 million ... ... Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: CTIC) today announced that ... Notes") due 2011 and 5,459,574 shares of its common stock,no par value ...
... Board of Directors of Shire plc (LSE: SHP,NASDAQ: ... announces its Board succession plans. Dr James H ... Emmens (56) will succeed him,as Non-Executive Chairman. Angus ... Board changes will become effective at Shire,s AGM ...
Cached Biology Technology:2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3Shire plc: Board Changes 2Shire plc: Board Changes 3Shire plc: Board Changes 4
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... alongside decades of in-depth monitoring, has provided unique ... a population of top-predators. Published in Nature ... seals have significantly altered in accordance with changes ... conditions. Despite a shift in the population towards ... through generations, leaving the population in decline. ...
(Date:7/23/2014)... tissue samples cultured from cystic fibrosis patients, scientists at ... Lung Institute have shown that a new CF drug ... drug. , The finding, published today in the journal ... CFTR protein becomes unstable and loses its ability to ... drugs. The research offers several insights into how novel ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... In an international human genetic study, researchers at UT Southwestern ... disease lupus, and its location on the X chromosome might ... the disease than males. Identifying this gene, IRAK1, as ... Chandra Mohan, professor of internal medicine and senior author of ...
... nervous system or brain. So how do individual bacterial ... a biofilm "decide" between different physiological processes (such as ... In the prestigious 2009 Fleming lecture, given ... (Monday 30 March) Dr Nicola Stanley-Wall from the University ...
... coastal mudflats have an essential role to play in ... by Dr Efe Aganbi and colleagues from the University ... meeting at Harrogate today (Monday 30 April), reveals essential ... depending on whether or not oxygen is present. In ...
Cached Biology News:Gene linked to lupus might explain gender difference in disease risk 2Microbes in mud flats clean up oil spill chemicals 2
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Desalt Spin Columns contain a proprietary high-performance ... exceptional desalting and protein-recovery characteristics compared to ... low as 25 g/ml of protein can ... > 95% retention of salts and other ...
Biology Products: